Lobbying

Moleculight's latest lobbying report covers Q2 2026, at $50K. The four quarters Q4 2025–Q3 2026 total $90K. Its first report covers Q2 2025; the issues it reports most are Medicare/Medicaid and Health Issues.

Moleculight

Latest quarter
No record
Q3 2026 · 0 reports
Last 12 months
$90K
Last 4 quarters
vs last quarter
−100.0%
Q3 2026 against the quarter before
First report
Q2 2025
The first quarter a report named it

Lobbying by quarter

Moleculight lobbying by quarter
Moleculight lobbying by quarter
QuarterAmountReports
Q2 2025$70K1
Q3 2025$30K1
Q4 2025$10K1
Q1 2026$30K1
Q2 2026$50K2
Q3 2026$00

By issue

  • Medicare and Medicaid$180K · 6 reports
  • Health issues$10K · 1 reports

An issue's amount splits each report's amount equally over the issues the report lists.

Who was lobbied

  • HOUSE OF REPRESENTATIVES6 reports
  • SENATE5 reports
  • Centers For Medicare and Medicaid Services (CMS)1 reports
  • Health & Human Services, Dept of (HHS)1 reports

Firms it paid

Firm
King & Spalding$170K5 quarters
Checkmate Government Relations$20K1 quarters

Former officials lobbying for it

Former position
JULIA RICHARDSON2015-2014 USCPSC Senior Counsel & Policy Advisor to Chairman; Director Office of Leg. Affts. 2012-2014 FEC Counsel to Commn. Chair & VP Chair; 2009-2014 US Senate Comm. on Rules & Admin. Senior Counsel & CounselQ2 2026
KENDRICK B MEEKU.S. Representative (FL-17) 2002-2010)Q2 2026
TIMOTHY LUCAS BLANCHATChief of Staff, Congressman Richard Hudson; Deputy State Director, Senator Thom TillisQ2 2026
SCOTT DZIENGELSKIRep. Murphy (PA-18): Leg. Dir. (2015-2017), Sr. Leg. Asst. (2013- 2015), Leg. Asst. (2012-2013), Leg. Corr. (2011-2012), Staff Asst. (2010-2011); Energy and Commerce Committee: Staff (2015-2017)Q1 2026

Lobbying reports

Filed by
07/20for Q2Checkmate Government Relations$20K
07/19for Q2King & Spalding$30K
07/14for Q2Checkmate Government RelationsUnder $5,000
04/20for Q1King & Spalding$30K
01/19for Q4 2025King & Spalding$10K
25/10/19for Q3 2025King & Spalding$30K
25/10/19for Q3 2025King & Spalding$30K
25/07/21for Q2 2025King & Spalding$70K
25/05/13for Q2 2025King & SpaldingUnder $5,000